ADC Demand Forecast Revised Downward
Daiichi Sankyo revised its forecast for antibody-drug conjugate (ADC) demand, attributing the change to clinical trial data, shifts in target patient populations, and delays in product launch timelines. According to the earnings presentation, the updated forecast now falls below the minimum purchase obligations specified in long-term agreements with contract manufacturing organizations (CMOs). The company recorded the $850 million charge earlier in its financial year as part of this reassessment.
“The terms reflected the limitations of Daiichi’s in-house capacity and the restricted number of CMOs capable of handling ADCs.” — Company statement
CMO Agreements and Supply Continuity Strategy
To ensure supply continuity, Daiichi Sankyo entered into long-term agreements with CMOs that include minimum purchase obligations and dedicated production lines. These agreements were designed to secure production capacity amid the limited number of CMOs globally with the technical capability to manufacture ADCs. The company noted that such constraints significantly influenced its decision-making process. The $850 million charge is directly linked to the shortfall between forecasted demand and the contractual minimums required under these agreements.
- ADC demand forecast now below minimum purchase obligations in CMO contracts
- Long-term CMO agreements include dedicated production lines and minimum purchase commitments
- Only a limited number of CMOs globally possess ADC manufacturing capability
Internal Capacity Plans Cancelled
As a result of the revised demand forecast, Daiichi Sankyo has pulled back from its previously announced plans to invest in ADC equipment at its Odawara plant in Japan. The company had initially intended to expand internal capacity to meet anticipated growth in ADC production. However, with demand falling short of expectations, the investment has been scrapped. This marks a significant pivot in the company’s manufacturing strategy, shifting from internal scale-up to reliance on contracted capacity.
Daiichi Sankyo reported $13.4 billion in revenue for 2025, despite the ADC-related setbacks. The company emphasized that the $850 million charge was a one-time adjustment tied to the revised forecast, not a reflection of long-term decline in ADC commercial viability.
Source: www.biospace.com
Compiled from international media by the SCI.AI editorial team.
